Modern endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer

Dilbar Muradovna Almuradova , Dilsora Ilhomovna Mukumova ,Xadicha Khasanovna Turaeva ,Karlibaev Azamat Orazbaevich

dc.contributor.author	Dilbar Muradovna Almuradova , Dilsora Ilhomovna Mukumova ,Xadicha Khasanovna Turaeva ,Karlibaev Azamat Orazbaevich
dc.date.accessioned	2022-10-12T14:12:59Z
dc.date.available	2022-10-12T14:12:59Z
dc.date.issued	2022
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/3803
dc.description.abstract	Breast cancer is the most common cancer affecting women, with a one in seven lifetime risk. Estrogen receptor-positive (ER-positive) breast cancer is the most common type of breast cancer diagnosed today.Each year, approximately two million women are diagnosed with breast cancer worldwide. Estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive breast cancer accounts for approximately 70% of all breast cancers, and 85% of those in women over 70 years of age.	en_US
dc.language.iso	other	en_US
dc.publisher	Other	en_US
dc.subject	Breast cancer, Estrogen receptor-positive, progesterone receptor (PgR)-positive breast cancer, endocrine therapy, locally advanced breast cancer (LABC)	en_US
dc.title	Modern endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer	en_US
dc.type	Article	en_US